Company: HRTX
Filing Date: 2025-08-28
Form Type: 8-K
Source: 0000950170-25-112048
Chunk: 0

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-08-28
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01 Entry Into a Material Definitive Agreement.

Heron Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an Office Lease Agreement (the “Lease”), dated as of August 22, 2025, with USEF HCG Fenton LLC, a Delaware limited liability company (the “Landlord”). The Lease is for the Company’s new corporate headquarters, which is approximately 16,837 rentable square feet (the “ Premises”) at 25 Fenton Main Street, Cary, North Carolina, 27511 (the “ Building”).

The Lease provides for a term of approximately one hundred eleven months. Under the terms of the Lease, the Tenant has the option to extend the Lease one time for a period of eighty-four additional months, by providing written notice to the Landlord not more than 18 months nor less than 12 months prior to the expiration date. In addition, during the term of the Lease, the Lease also provides the Tenant with a one-time “right of first refusal” with respect to any vacant space contiguous to the Premises, when such space becomes available for lease, subject to any terms provided by the Landlord in connection with the offer to lease such space.

Beginning on the Commencement Date (the “Term Commencement Date”), the Company’s monthly base rent under the Lease will be $614,550.50 for the first 12-month term, which will increase by a certain percentage per each subsequent 12-month term, and will also be responsible for paying its proportionate share of operating costs; provided, that base rent and estimated operating costs will be abated during a certain number of months after the Term Commencement Date.

The Lease contains customary representations, warranties, and covenants.

The foregoing description of the Lease is not complete and is qualified in its entirety by reference to the complete terms and conditions of the Lease. A copy of the Lease will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the period ending September 30, 2025.

Item 9.01 Financial Statements and Exhibits.